Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PNT2002

            Therapeutic Area: Oncology Product Name: PNT2002

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing August 04, 2020

            Details:

            Financing will be used to strengthen POINT’s position as a leader in radioligand development which includes PNT2002, a 177Lu-PSMA radiotherapeutic to treat prostate cancer and commercialization through investment in their pipeline as well as manufacturing capabilities.